INTRODUCTION
Type 2 diabetes mellitus (T2D) is characterized by reduced insulin sensitivity of insulin target tissues and impaired insulin secretion by pancreatic beta cells. Although both of these factors play a role, genetic studies suggest that the ability of beta cells to respond to metabolic stressors is the predominant factor in determining the predisposition to T2D (Muoio and Newgard, 2008) .
In T2D, beta cells exhibit an impaired capacity to compensate for increased insulin demand (Cerasi and Luft, 1967) , a defect that has been ascribed to both inadequate cellular capacity to secrete insulin (Hosker et al., 1989) and beta cell death (Butler et al., 2003) . Among the earliest defects observed in T2D patients is a reduced ability of beta cells to secrete insulin in response to elevated blood glucose levels (Hosker et al., 1989) . This impairment in glucose-stimulated insulin secretion has been attributed to defects in glucose sensing (Froguel et al., 1992) , mitochondrial dysfunction (Supale et al., 2012) , and oxidative stress (Robertson, 2004) . Thus, mounting evidence suggests that defects in multiple cellular processes can compromise beta cell function and could be a factor in T2D development. Furthermore, hyperglycemia has been shown to impair the expression of genes that are important for beta cell identity (Jonas et al., 1999) . More recently, Talchai et al. (2012) described a loss of beta cell features, characterized by a decline in insulin production, acquisition of progenitor-like characteristics, and fate conversion into other endocrine cell types in mouse models of T2D, suggesting that loss of the differentiated beta cell state also contributes to beta cell failure in T2D. However, it is currently unknown whether the loss of beta cell functional properties (namely, regulated insulin secretion) and loss of beta cell identity are linked during T2D progression. A simultaneous loss of beta cell function and identity could be explained by reduced expression of a central transcriptional regulator controlling genes involved in both processes.
Several lines of evidence suggest that the beta-cell-enriched transcription factor Nkx6.1 could have a role in T2D. First, genome-wide association studies suggest that variants of Nkx6.1 associate with T2D (Yokoi et al., 2006) . Second, decreased Nkx6.1 expression has been shown to accompany the development of T2D in rodents and humans (Guo et al., 2013; Talchai et al., 2012) . Third, in vitro studies in beta cell lines and isolated islets suggest a possible role for Nkx6.1 in the regulation of glucose-stimulated insulin secretion as well as beta cell proliferation (Schisler et al., 2005 (Schisler et al., , 2008 . Additionally, we recently showed that Nkx6.1 is necessary and sufficient to confer beta cell identity to differentiating endocrine precursors in the embryo (Schaffer et al., 2013) , raising the possibility that Nkx6.1 could also help maintain the differentiated state of adult beta cells. Together, these findings suggest that Nkx6.1 may be a regulator of beta cell function and identity in adult animals.
To explore the role of Nkx6.1 in mature beta cells, we ablated Nkx6.1 specifically in beta cells of adult mice and identified Nkx6.1 target genes in beta cells by combining gene-expression profiling and chromatin immunoprecipitation with massively parallel sequencing (ChIP-seq). We found that loss of Nkx6.1 caused rapid-onset diabetes due to defects in insulin biosynthesis and secretion. The observed loss in insulin production and beta cell functional properties was later accompanied by ectopic activation of delta cell genes in beta cells. Thus, by impairing beta cell function and destabilizing beta cell identity, (F and G) Nkx6.1 Dadultb mice have lower plasma insulin levels and elevated blood glucose after a glucose stimulus compared with control mice (n = 6).
(legend continued on next page) 1I , and 1J). To determine whether Nkx6.1 deletion affects beta cell function, we conducted glucose tolerance tests and measured blood glucose levels. Glucose tolerance tests performed 1 week after the last tamoxifen injection revealed elevated fasting blood glucose levels and glucose intolerance in male Nkx6.1 Dadultb mice when compared with tamoxifen-treated and non-tamoxifen-treated control mice ( Figure 1D ). Likewise, blood glucose levels were significantly elevated in Nkx6.1
Dadultb mice fed ad libitum, with levels reaching near 500 mg/dl within 8 weeks after the last tamoxifen injection ( Figure 1E ). caused by insulin insufficiency, we measured plasma insulin levels after glucose administration. As expected, control mice responded to a glucose bolus with a rapid increase in plasma insulin levels within 5 min of glucose administration ( Figure 1F ). By contrast, insulin levels did not increase in Nkx6.1 Dadultb mice and blood glucose levels were significantly higher than in control mice (Figures 1F and 1G Table S1 ), of which 887 were upregulated and 568 were downregulated. To define the cellular processes affected by Nkx6.1 inactivation, we performed Gene Ontology (GO) analysis of the differentially expressed genes. Consistent with the diabetic phenotype, Nkx6.1-regulated genes showed association with biological processes that are critical for beta cell function, such as ion transport, regulation of secretion, oxidation reduction, insulin secretion, and hexose biosynthesis ( Figure 2B ). These data suggest that reduced insulin production may not be the only cause of hyperglycemia following Nkx6.1 deletion, and that simultaneous impairment of multiple processes required for proper beta cell function could contribute to the development of diabetes in Nkx6.1 Dadultb mice.
To distinguish between direct transcriptional target genes of Nkx6.1 and genes indirectly affected by Nkx6.1 inactivation, we performed ChIP-seq for Nkx6.1 on primary mouse islets to identify Nkx6.1-occupied genes. We detected a total of 6,771 Nkx6.1 binding regions throughout the murine genome (FDR < 0.001; Table S2), 4,066 of which were near genes or intronic ( Figure 2C ). De novo motif analysis revealed a TAAT core motif and two flanking nucleotides on each side as the sequence motif preferentially occupied by Nkx6.1 ( Figure 2D) . Notably, the TAAT core of the Nkx6.1 de novo binding motif was previously identified by an in vitro electrophoretic mobility shift assay (Jørgensen et al., 1999) . The TAAT motif is shared among many homeodomain transcription factors (Wilson et al., 1996) , demonstrating binding of Nkx6.1 to the core homeodomain-binding motif.
Next, to determine the overlap between the genes occupied by Nkx6.1 in beta cells and genes whose expression is affected by Nkx6.1 loss, we analyzed which of the 1,988 Nkx6.1 binding sites within 10 kb of a transcriptional start site were associated with genes significantly regulated in Nkx6.1-deficient islets. See also Figure S3 and Tables S1, S2, and S3 .
Surprisingly, only 8% of Nkx6.1-occupied genes (135/1,818) were also regulated by Nkx6.1 ( Figure 2E ; Table S3 ). Similarly, of the 1,455 genes with statistically significant changes in expression, only 9% were bound by Nkx6.1 ( Figure 2E ), indicating that only a fraction of the genes affected by Nkx6.1 inactivation depend directly on transcriptional input by Nkx6.1. Statistical analysis using hypergeometric distribution (Bhinge et al., 2007) revealed that this overlap between Nkx6.1-bound and -regulated genes was still significantly greater than randomly expected (p < 0.05). Interestingly, an equal percentage of Nkx6.1-bound and -regulated genes were upregulated as were downregulated (Figures 2F and 2G) , suggesting that Nkx6.1 can act as both a transcriptional repressor and activator. Nkx6.1 was found to directly regulate various critical beta cell genes, including genes involved in glucose uptake and metabolism (Slc2a2 [Glut2], Pcx, and G6pc2) and insulin processing (Ero1lb and Slc30a8), as well as transcriptional regulators with known roles in islet development and/or beta cell function (MafA, Rfx6, Mnx1, and Tle3; Figure 2E ). These results suggest that Nkx6.1 exerts its function by transcriptionally regulating mediators of multiple beta cell processes.
The Insulin Secretory Response Is Impaired after Nkx6.1 Inactivation The insulin secretory response of beta cells is regulated by the coupling of glucose metabolism to insulin secretion (Muoio and Newgard, 2008) . Glycolysis results in an increase in the ATP:ADP ratio, which serves as the key trigger for closure of ATP-sensitive potassium channels (K ATP channels), ultimately stimulating calcium influx and insulin secretion. Because Nkx6.1 directly regulates the glucose metabolic genes Glut2, Pcx, and G6pc2 (Table  S1 ; Figures 3A-3C ), we hypothesized that glucose uptake, glycolytic flux, and energy production could be impaired in Nkx6.1-deficient beta cells. Supporting the conclusion that the downregulation of Glut2 is physiologically significant, we found that Nkx6.1 Dadultb mice were resistant to streptozotocin-induced beta cell death (data not shown), which depends on Glut2-mediated uptake of streptozotocin (Schnedl et al., 1994) . To investigate whether the changes in expression of glucose metabolic genes are associated with defects in energy production, we stained pancreata for phospho-AMP kinase (p-AMPK), a sensitive indicator of cellular energy depletion (low ATP:AMP ratio; Porat et al., 2011) . Nkx6.1
Dadultb islets displayed strikingly more intense p-AMPK staining than control islets (Figures 3D-3E 0 ), indicating that loss of Nkx6.1 causes reduced glycolytic flux and energy stress. Further supporting this conclusion, intracellular ATP content was also significantly decreased in Nkx6.1
Dadultb islets ( Figure 3F ). We conclude that despite increased blood glucose levels, Nkx6.1 deficiency results in energy-depleted beta cells. Since energy depletion has been shown to impair insulin secretion and cause diabetes in mice (Piston et al., 1999; Porat et al., 2011; Terauchi et al., 1995) , the defect in energy production in Nkx6.1 Dadultb mice could lead to a severely impaired insulin secretory response. In addition to affecting ATP production, Nkx6.1 deletion also led to reduced expression of Sytl4, a vesicle-associated protein that has been implicated in the modulation of insulin secretion (Gomi et al., 2005) , as well as Ucn3 and Glp1r (Figures 3G-3I ), which are involved in peptide-mediated potentiation of insulin secretion (Li et al., 2007; Preitner et al., 2004) . These changes in gene expression suggest that Nkx6.1 also has glucose-metabolism-independent roles in insulin secretion. Notably, core components of the stimulus-secretion-coupling mechanism (e.g., Abcc8, Kcnj11, and Cacna1c) and genes encoding proteins important for vesicle docking (e.g., Pclo and Noc2) were normally expressed in Nkx6.1-deficient islets ( Figure 3G ).
To directly test whether the observed changes in gene expression affect insulin secretion at a functional level, we performed in vitro glucose-stimulated insulin secretion (GSIS) assays on isolated islets from Nkx6. (Guillam et al., 2000) , suggesting that loss of Glut2 in Nkx6.1 Dadultb beta cells makes a major contribution to the insulin secretory defect. Notably, additional defects downstream of K ATP channel-mediated membrane depolarization also appear to exist, as insulin secretion in Nkx6.1-deficient islets was also reduced in response to membrane depolarization and calcium influx (30 mM KCl and 2 mM Bay K8644, respectively; Figure 3J ). Together, these results imply that impaired insulin secretion is a major contributor to the diabetic phenotype of Nkx6.1 Dadultb mice.
Decreased Beta Cell Proliferation in Nkx6.1 Dadultb Mice
It has been suggested that glycolytic flux and ATP production serve as a trigger for beta cell replication . Specifically, glucose metabolism is thought to control beta cell proliferation by regulating expression of Cyclin D2 (Ccnd2) (Salpeter et al., 2010 (Salpeter et al., , 2011 , which is a critical regulator of beta cell mass in mice (Georgia and Bhushan, 2004; Kushner et al., 2005) . Since Nkx6.1-deficient beta cells have defects in energy production, we examined whether Nkx6.1 deletion affects Ccnd2 messenger RNA (mRNA) levels. We found that Ccnd2 mRNA levels were indeed decreased in Nkx6.1 Dadultb islets (Table S1 ; Figure 4A ).
Strikingly, Nkx6.1 inactivation specifically affected Ccnd2, whereas the mRNA levels of other cyclins were unaffected (Table  S1 ; Figure 4A (B-E') Immunofluorescence staining of pancreata from Nkx6.1 Dadultb and control mice at 6 weeks.
(F) ATP measurement in islets from Nkx6.1 Dadultb and control mice at 6 weeks (n = 8).
(G) qRT-PCR analysis of islets from Nkx6.1 Dadultb and control mice at 6 weeks for genes involved in insulin secretion (n = 3).
(H and I) Immunofluorescence staining for Ucn3 in Nkx6.1 Dadultb and control pancreata at 6 weeks. regulatory sequences (Table S2 ), suggesting that the regulation of Ccnd2 by Nkx6.1 could be indirect.
Restoring Glucose Import Reinstates Ccnd2 Expression in Nkx6.1 Dadultb Islets
To explore whether limited glucose uptake capacity due to loss of Glut2 could be the main cause of reduced Ccnd2 expression in Nkx6.1-deficient islets, we investigated whether restoring Glut2-mediated glucose import could increase Ccnd2 levels after Nkx6.1 inactivation. To examine this, we reconstituted Glut2 expression in Nkx6.1 Dadultb islets using an adenovirus containing Glut2 complementary DNA (cDNA; Ad-Glut2), which resulted in a 25-fold increase in Glut2 mRNA levels compared with Ad-b-gal-treated control islets, and restored Glut2 protein expression ( Figures 4F and S4 ). Glut2 reconstitution increased Ccnd2 expression to the levels of the control islets, whereas expression of other Nkx6.1-regulated genes remained significantly reduced ( Figure 4F ). Glut2 reconstitution in Nkx6.1
Dadultb islets also restored the number of insulin + cells expressing Ki67
to control values ( Figure 4G ), indicating that Glut2 reexpression rescues the proliferation defect. These findings demonstrate that Ccnd2 expression does not depend on direct transcriptional input from Nkx6.1, and that Nkx6.1 controls Ccnd2 and beta cell proliferation indirectly by regulating glucose import. Consistent with the notion that glycolytic flux regulates Ccnd2 expression via the stimulus-secretion-coupling pathway (Salpeter et al., 2010 (Salpeter et al., , 2011 , increasing calcium influx by treating islets with the L-type-dependent calcium channel opener Bay K8644 similarly restored Ccnd2 expression in Nkx6.1
Dadultb islets ( Figure 4H ). Significantly, Bay K8644 administration to mice increased the number of insulin + cells expressing Ki67 to control values ( Figure 4I ), providing in vivo evidence that beta cell proliferation can be rescued by stimulating calcium influx. In contrast, culture of Nkx6.1-deficient islets in the presence of an activator for the rate-limiting enzyme of glycolysis, glucokinase, or the beta cell mitogen, insulin (Paris et al., 2003) , failed to restore Ccnd2 expression (Figures 4J and 4K ; also compare with Figure 4A ). These findings illustrate that the proliferative capacity of beta cells is coupled to glucose metabolism and that Nkx6.1 controls this process by regulating Glut2 expression. Because beta cells have a low turnover rate in adult mice , the observed reduction in beta cell proliferation did not result in decreased beta cell mass in our acute Nkx6.1 deletion model ( Figures S2G and S2H) . However, the decreased proliferative capacity could become metabolically relevant when beta cells need to undergo adaptive expansion under conditions of increased insulin demand.
Nkx6.1 Dadultb Mice Have Posttranscriptional Defects in Insulin Biosynthesis
Our gene expression and ChIP-seq analysis revealed that Nkx6.1 also controlled genes required for insulin biosynthesis, which could explain the reduction in pancreatic insulin levels in Nkx6.1 Dadultb mice. Most notably, expression of the T2D-associated zinc transporter Slc30a8, the oxidoreductase Ero1lb, and the proinsulin-to-insulin convertase Pcsk1 (PC1) was severely reduced in Nkx6.1-deficient beta cells (Table S1 ; Figures 5A-5E ). These proteins have established roles in insulin processing and/or maturation of insulin secretory vesicles (Bellomo et al., 2011; Zhu et al., 2002; Zito et al., 2010) , implying a role for Nkx6.1 in multiple aspects of the insulin biosynthesis pathway. Notably, the finding that Ins1 and Ins2 mRNA levels were not significantly changed (Table S1 ; Figure 5F ) suggests that reduced insulin production in Nkx6.1 Dadultb mice is mainly caused by posttranscriptional defects in insulin biosynthesis.
To further define which steps in insulin biosynthesis are affected by Nkx6.1 inactivation, we measured pancreatic proinsulin content and calculated the insulin-to-proinsulin ratio in Nkx6.1
Dadultb islets. Compared with control mice, pancreatic proinsulin levels and the ratio of insulin to proinsulin were significantly reduced in Nkx6.1 Dadultb mice ( Figures 5G and 5H ). Although the defect in proinsulin-to-insulin processing was expected based on the observed decrease in Slc30a8, Ero1lb, and Pcsk1 expression, it is less clear why loss of Nkx6.1 impairs proinsulin biosynthesis. Because glucose is a direct stimulator of proinsulin translation (Wicksteed et al., 2003) , we examined whether decreased Glut2 expression in Nkx6.1
Dadultb mice limits the intracellular availability of glucose and in turn reduces proinsulin production. However, restoring Glut2 expression in Nkx6.1 Dadultb -dispersed islets had no effect on proinsulin or insulin levels ( Figures S5A and S5B ), suggesting that reduced expression of insulin biosynthetic enzymes, rather than glucose import, limits proinsulin synthesis in Nkx6.1 Dadultb mice.
To determine whether the defect in insulin biosynthesis affects the formation of insulin secretory vesicles, we examined secretory vesicle numbers and morphology in beta cells from Nkx6.1
Dadultb and control mice. According to the guidelines established by Pictet et al. (1972) , secretory vesicles were considered immature if they had a homogeneous light gray appearance similar to the electron density of the cytoplasm, or mature if the vesicles contained an electron-dense granule darker than the density of the cytoplasm. Transmission electron microscopy (TEM) showed that the overall number of secretory granules was unchanged ( Figures 5I-5K 0 , blue arrowheads), a feature that reflects reduced processing of proinsulin to insulin (Orci et al., 1984) . Moreover, the proportion of immature vesicles was significantly increased in Nkx6.1-deficient beta cells ( Figure 5M ), representing another feature of impaired insulin processing. These findings demonstrate that changes in the expression of insulin biosynthesisassociated genes after Nkx6.1 deletion manifest as defects in insulin processing and mature insulin secretory vesicle formation. Given previous evidence that deletion of Ero1lb and Slc30a8 in mice perturbs glucose homeostasis (Nicolson et al., 2009; Zito et al., 2010) , these defects in insulin biosynthesis together with the impaired insulin secretory response are likely the predominant cause of diabetes in Nkx6.1 Dadultb mice. 
Nkx6.1 Inactivation Destabilizes Beta Cell Identity
In T2D mouse models of metabolic stress, reduced beta cell insulin production is associated with a decrease in Nkx6.1, Pdx1, and NeuroD expression, as well as increased expression of the pancreatic progenitor cell marker Ngn3 and the pluripotency markers Oct4, Nanog, and L-Myc (Talchai et al., 2012) . Because a subset of metabolically stressed beta cells eventually adopt other endocrine fates, it has been proposed that beta cell dedifferentiation followed by conversion into other endocrine cell types could cause beta cell failure in T2D (Talchai et al., 2012) . Although Nkx6.1 deletion did not affect the expression of Pdx1, NeuroD, or pluripotency markers (Table S1 ; Figures 6A, 6C , and 6E), we observed robust induction of Ngn3 expression in beta cells similar to what has been observed in models of metabolic stress (Table S1 ; Figures 6A, 6B, 6D , and 6F (Figures 6G-6L ). This finding is consistent with our previous observation of a betato-delta cell fate switch after Nkx6.1 ablation in embryonic beta cells (Schaffer et al., 2013) and suggests that, although it does not happen immediately, Nkx6.1 inactivation in adult beta cells causes beta cells to adopt a delta cell identity over time. In conjunction with our previous findings, these data strongly suggest that loss of Nkx6.1 in adult mice destabilizes beta cell identity, eventually leading to fate conversion of beta into delta cells. Together, our analysis demonstrates that Nkx6.1 is a critical regulator of insulin biosynthesis and secretion, as well as proliferative capacity and cell identity in adult beta cells. The severe beta cell defects observed after Nkx6.1 inactivation suggest that restoring Nkx6.1 levels could be a therapeutic strategy in T2D.
DISCUSSION
It is widely recognized that beta cell dysfunction, specifically the inability of beta cells to properly secrete insulin in response to high blood glucose levels, is among the earliest clinical features during progression to T2D (Ferrannini, 2010) . The ability to sense glucose levels and to couple this information to an insulin secretory response is bestowed upon beta cells by specialized transporters and enzymes. Although the mechanisms that underlie glucose-mediated insulin secretion are fairly well understood, it has remained unclear which transcriptional regulators initiate and maintain the expression of genes that enable beta cells to perform their highly specialized function. In this study, we show that the transcription factor Nkx6.1 is a master regulator of genes that define the functional beta cell state, a role that is consistent with its exclusive expression in beta cells of the adult pancreas.
We show that conditional inactivation of Nkx6.1 in beta cells of adult mice results in overt diabetes within days of Nkx6.1 ablation. Loss of Nkx6.1 activity had an immediate and dramatic impact on the expression of genes that give beta cells their unique ability to synthesize and release insulin in a regulated fashion. We found that genes involved in insulin biosynthesis (Slc30a8 and Ero1lb), glucose import (Glut2), and glucose metabolism (Pcx) are direct transcriptional target genes of Nkx6.1. In addition, Nkx6.1 ablation indirectly affected the expression of numerous genes that are important for beta cell function and, interestingly, also beta cell proliferation (Figure 7) . The finding that islet Ccnd2 levels and beta cell proliferation were decreased in Nkx6.1 conditional mutant mice was somewhat surprising, as several studies have shown that hyperglycemia has a stimulatory effect on beta cell Ccnd2 expression and self-renewal (Alonso et al., 2007; Bonner-Weir et al., 1989; Salpeter et al., 2011) . We found that reduced availability of the beta cell mitogen insulin (Paris et al., 2003) made no apparent contribution to the reduced proliferative capacity of beta cells after Nkx6.1 ablation. Instead, our results suggest that the proliferative capacity of Nkx6.1-deficient beta cells is limited by the reduced intracellular availability of glucose due to loss of Glut2 expression (Figure 7 ). These findings demonstrate an intricate link between the beta cell's ability to import glucose and its proliferative capacity, which lends further support to the emerging concept that glucose metabolism plays a critical role in the regulation of beta cell proliferation Salpeter et al., 2010 Salpeter et al., , 2011 . Combined with the finding that Nkx6.1 levels are reduced in T2D models of metabolic stress (Talchai et al., 2012) , our work suggests that Nkx6.1 acts as a metabolic sensor that modulates both insulin secretion and proliferative capacity in response to metabolic stress. By preventing the proliferation of beta cells that have lost glucose responsiveness, the cell-autonomous coupling of glucose import to beta cell proliferation might provide an inherent selection mechanism for healthy beta cells.
Our study also reconciles previously reported, seemingly contradictory findings about the role of Nkx6.1 in beta cell proliferation. We recently reported that transgenic overexpression of Nkx6.1 in beta cells of adult mice in vivo had no positive effect on beta cell proliferation or beta cell mass (Schaffer et al., 2011) . By contrast, virus-mediated expression of Nkx6.1 in cultured islets had proproliferative activity (Schisler et al., 2008) . A possible explanation for this apparent contradiction is that in vitro culture of islets compromises Nkx6.1 expression levels. It is known that once they are removed from their niche and put into culture, beta cells quickly lose Glut2 expression and cease to proliferate (Weinberg et al., 2007) , indicating that expression of upstream Glut2 regulators, including Nkx6.1, could also be compromised. Thus, the observed proproliferative effect of Nkx6.1 in vitro may be explained by virally expressed Nkx6.1 restoring reduced Nkx6.1 levels and, in turn, also Glut2 and Ccnd2 levels in cultured islets. By contrast, increasing Nkx6.1 levels above normal in healthy beta cells in vivo appears to have no further stimulatory effect on glucose import and beta cell proliferation. After Nkx6.1 deletion, we observed an extremely rapid decline in beta cell insulin content. The loss of insulin was not associated with beta cell death, revealing a striking similarity between Nkx6.1-deficient beta cells and ''empty'' beta cells observed in mouse models of T2D (Talchai et al., 2012) . Furthermore, as reported under conditions of metabolic stress (Talchai et al., 2012) , we found that reduced Nkx6.1 expression was also accompanied by derepression of the endocrine progenitor cell marker Ngn3. Based on the observation that beta cells undergo fate conversion into non-beta endocrine cell types in T2D models (Talchai et al., 2012) , the loss of beta cell features and gain of Ngn3 expression has been proposed to render beta cells plastic and more prone to changing their identity.
Consistent with this notion, we observed that a subset of Nkx6.1-deficient beta cells ectopically expressed somatostatin 8 weeks after Nkx6.1 deletion. Previously, we showed with lineage tracing studies that Nkx6.1 deletion in embryonic beta cells leads to a rapid beta-to-delta cell fate switch (Schaffer et al., 2013) . However, conversion of beta cells into other non-beta endocrine cell types was not observed after Nkx6.1 inactivation in embryonic beta cells. Similarly, after Nkx6.1 deletion in adult beta cells, we observed coexpression of insulin exclusively with somatostatin and no other pancreatic hormones. Thus, loss of Nkx6.1 leads to selective derepression of delta cell genes in both embryonic and adult beta cells. However, fate conversion is more complete and occurs more rapidly when Nkx6.1 is inactivated in immature beta cells. Therefore, a sequential loss of beta cell traits preceding the adoption of alternative endocrine cell fates seen after adult Nkx6.1 inactivation closely mirrors the gradual loss of functional beta cell mass observed in T2D models (Talchai et al., 2012) .
Our study provides support for an evolving concept that transcription factors, such as Nkx6.1 and FoxO1 (Talchai et al., 2012) , are critical for maintaining beta cells in their differentiated state. A key question that requires further exploration is whether a destabilized beta cell state is observed in humans and possibly contributes to the pathogenesis of T2D. The observation that NKX6.1 expression is decreased in beta cells from humans with T2D (Guo et al., 2013) suggests that findings in rodent models might indeed be relevant to human disease. Future studies will need to explore which aspects of the rodent phenotype are also found in humans and how loss of beta cell features relates to disease progression. Such knowledge could identify a window for therapeutic intervention during which the functional beta cell state could be restored before beta cells convert into other endocrine cell types.
EXPERIMENTAL PROCEDURES

Mouse Strains
The following mouse strains were utilized in this study: Pdx1CreER TM (Gu et al., 2002) , Nkx6.1 +/À (Sander et al., 2000) , and Nkx6.1 flox (Schaffer et al., 2013) . All animals carrying the Nkx6.1 flox allele were maintained on a mixed 129Sv/ C57Bl6/J genetic background. Unless otherwise stated in the text, male mice were used for the experiments. Tamoxifen (Sigma) was dissolved in corn oil at 20 mg/ml, and 2 mg was injected subcutaneously four times over a 2-week period. All animal experiments were approved by the Institutional Animal Care and Use Committees of the University of California, San Diego.
Tissue Preparation and Immunohistochemistry
Tissue preparation, immunofluorescence staining, TUNEL assays, and morphometry were performed as previously described (Schaffer et al., 2010 (Schaffer et al., , 2013 . A description of the antibodies used (Tables S4 and S5 ) and detailed methods are provided in the Extended Experimental Procedures.
Microscopy and Image Analysis
All immunofluorescent images were acquired using a Zeiss AxioOberver.Z1 microscope (Carl Zeiss) with the Zeiss ApoTome module and processed in Zeiss AxioVision Release 4.8 and Adobe Photoshop CS5.1. Only brightness and contrast was adjusted in images in accordance with the Journal of Cell Biology figure manipulation guidelines.
Glucose Tolerance Tests, GSIS Assays, and Insulin and Proinsulin Measurements Glucose tolerance tests, GSIS assays, and insulin measurements were performed as previously described (Schaffer et al., 2011) . Proinsulin measurements were performed on whole pancreatic lysates using a mouse proinsulin ELISA (ALPCO). Details are described in the Extended Experimental Procedures.
Islet Isolation and Culture
Islet isolations were performed as previously described (Schaffer et al., 2011) with Liberase TL (Roche). For incubation of islets with chemical compounds, RPMI supplemented with 2.7 mM glucose and 1% BSA was used. Nkx6.1 Dadultb islets were incubated with 100 nM recombinant insulin (Sigma), 60 mM ± Bay K8644 (Sigma), or 10 mM glucokinase activator (GKA; EMD Calbiochem), and control islets were incubated with DMSO (ATCC) for 3 hr. For infection of islets with Ad-Glut2 and Ad-b-gal, the islets were dispersed and plated before infection as described previously (Fiaschi-Taesch et al., 2009) . Further details are provided in the Extended Experimental Procedures.
Microarray and qRT-PCR RNA was isolated from islets obtained from six littermate control and six Nkx6.1 Dadultb mice. Islets from two mice of identical genotypes were pooled to generate three independent cDNA probes per genotype for array hybridization. Labeled cDNA was hybridized to whole-mouse gene-expression G2519F microarrays (Agilent Technologies). A detailed description of the microarray and qRT-PCR analyses and a list of the primer sequences (Table S6) can be found in the Extended Experimental Procedures.
ChIP-Seq
ChIP was performed as previously described (Schaffer et al., 2013) with rabbit anti-Nkx6.1 antiserum (1:250) on sheared chromatin obtained from $10,000 islet equivalents (1,000 cells per islet) isolated from C57BL/6J mice. ChIPseq libraries were prepared according to Illumina's instructions (http://www. illumina.com). Sequencing was performed on an Illumina/Solexa Genome Analyzer II in accordance with the manufacturer's protocols. Data analysis was performed using Hypergeometric Optimization of Motif EnRichment (HOMER) (Heinz et al., 2010) . Peak annotation and de novo motif analysis were performed using HOMER, and venn diagrams were generated using BioVenn (Hulsen et al., 2008) . See the Extended Experimental Procedures for details.
Statistics
Unless otherwise stated, all values are shown as mean ± SEM; p values were calculated using an unpaired Student's t test in Microsoft Excel, and hypergeometric distribution was determined using R; p < 0.05 was considered significant.
ACCESSION NUMBERS
The NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) accession number for the microarray data set reported in this paper is GSE40470. The GEO accession number for the ChIP-seq data set reported in this paper is GSE40975. Nkx6.1 directly regulates transcription of genes encoding proteins involved in glucose uptake and metabolism (Glut2 and Pcx) and insulin biosynthesis (Ero1lb and Slc30a8). Reduced expression of these Nkx6.1 target genes affects beta cell function in three ways: First, decreased glucose uptake and metabolism diminishes ATP production, leading to impaired insulin secretion via the stimulus-secretion coupling pathway. Second, by enabling glucose uptake through Glut2 regulation, Nkx6.1 indirectly controls beta cell proliferative capacity. In the absence of Nkx6.1, expression of Ccnd2, which encodes the critical beta cell mitogen Cyclin D2, is reduced and beta cell proliferation is decreased. Reconstituting Glut2 expression in Nkx6.1-deficient beta cells restores Ccnd2 levels and beta cell proliferation. Third, insulin biosynthesis is severely impaired, leading to reduced production of mature insulin and an overabundance of immature secretory vesicles. Gck, glucokinase; Glut2, glucose transporter 2; K ATP , ATP-sensitive potassium channel; Pcx, pyruvate carboxylase.
SUPPLEMENTAL INFORMATION
